Achilles Therapeutics will use a customized digital manufacturing system to support its T cell therapy programs.

Developer and manufacturer of management systems for cell and gene therapies Autolomous will supply a bespoke version of its AutoIoMATE technology to T cell developer Achilles. Terms of the partnership have not been disclosed.

“The AutoloMATE platform is an out-of-the-box system, which we configure and validate for the individual requirements of our customers,” Kwok Pang chief operating officer at Autolomous told BioProcess Insider. “Autolomous continually adds new functionalities to the AutoloMATE platform to follow our customer focused strategy.”

Image: iStock/vittaya25

According to the firm, the partnership will help progress certain R&D programs towards a fully closed commercial process, with

Achilles will use the platform to manage the manufacturing of its T-cell therapies that are in development to treat solid tumors and help progress them towards a fully closed commercial process.

Initially, project activity will include deploying and integrating the AutoloMATE platform to support operations. This includes electronic batch production records.

The platform is anticipated to support the expansion of Achilles’ manufacturing, as well as streamlining its vein-to-vein time.

The collaboration is open ended and Pang told us it has “a view to grow in alignment with the Achilles commercialization strategy.”

He continued: “Deployment of  Autolomous’ digitized manufacturing platform empowers Achilles’ highly skilled manufacturing team to focus on manufacturing processes while AutoloMATE handles data management and data integrity, providing all stakeholders the confidence to make efficient, informed decisions.”